In human pancreatic EPP85-181P (181P) cells treated with Betulin in dilution series, the sulphorhodamine B staining proliferation assay reported a value of 21.09 μM. In MHCC97-H cells carrying a reporter with a SREBP-1-binding element, Betulin decreased luciferase activity in a dose-dependent manner compared with the vehicle control. In RAW 264.7 cells, Betulin at 9, 18 and 36 μM for 6 h increased Nrf2 translocation from the cytoplasm to the nucleus. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Betulin in a pancreatic cell proliferation assay
Cell-based study · human pancreatic cell line EPP85-181P (181P) [1]
Human pancreatic cell line EPP85-181P (181P) was treated with Betulin in dilution series. The sulphorhodamine B staining-based proliferation assay reported a value of 21.09 μM.
Literature-Reported Treatment Conditions
- Exposure duration
- After attachment for 24 h, substances were added in dilution series for a 5-day incubation
- Method
- substances were added in dilution series
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: dose, control.
Methods and source locations
Compound reported in the paper: Betulin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
3. Experimental > 3.4. Purification of the betulin from the extract (S17); 3. Experimental > 3.8. Cell lines (S27); 3. Experimental > 3.10. Cell proliferation assay (S29, S31, S33); Table 1 (T1.h1, T1.r1)
proliferation assay based on sulphorhodamine B (SRB) staining: proliferation assay based on sulphorhodamine B (SRB) staining — 3. Experimental > 3.10. Cell proliferation assay (S29); Table 1 (T1.h1, T1.r1)
Betulin decreases reporter activity in MHCC97-H cells
Cell-based study · MHCC97-H cells [2]
MHCC97-H cells carrying a luciferase reporter vector with a SREBP-1-binding element were treated with Betulin. Luciferase activity decreased in a dose-dependent manner compared with the vehicle control.
Literature-Reported Treatment Conditions
- Reported limits
- Not stated in the sentences used: dose, route, schedule, vehicle.
Methods and source locations
Compound reported in the paper: Betulin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > SREBP-1 promotes HCC cell proliferation and metastasis (S63, S64)
luciferase activity: luciferase activity; comparator: vehicle control — Results > SREBP-1 promotes HCC cell proliferation and metastasis (S63, S64)
Betulin increases nuclear translocation of Nrf2
Cell-based study · RAW 264.7 cells [3]
RAW 264.7 cells were treated with Betulin at 9, 18 and 36 μM for 6 h. Treatment increased Nrf2 translocation from the cytoplasm to the nucleus.
Literature-Reported Treatment Conditions
- Treatment concentration
- 9, 18 and 36 μM
- Exposure duration
- for 6 h
- Method
- treated with betulin
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Betulin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Effects of betulin on Nrf2 translocation, Keap1 and antioxidant enzyme expression (S2); Figure 1 legend (S80, S81, S85)
Nuclear and cytoplasmic extracts from RAW 264.7 cells were prepared for detecting Nrf2: Nuclear and cytoplasmic extracts from RAW 264.7 cells were prepared for detecting Nrf2; comparator: the control group — Results > Effects of betulin on Nrf2 translocation, Keap1 and antioxidant enzyme expression (S2); Figure 1 legend (S80, S81)